| scholarly article | Q13442814 |
| P2093 | author name string | Larisa H Cavallari | |
| Yang Dai | |||
| Shitalben R Patel | |||
| Vicki L Groo | |||
| Thomas D Stamos | |||
| Marlos A G Viana | |||
| P2860 | cites work | Clinical factors associated with hyperkalemia in patients with congestive heart failure. | Q46492458 |
| Racial differences in potassium response to spironolactone in heart failure | Q46598462 | ||
| Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program | Q46904673 | ||
| Point mutations close to the AUG initiator codon affect the efficiency of translation of rat preproinsulin in vivo | Q28272278 | ||
| Common variants in genes underlying monogenic hypertension and hypotension and blood pressure in the general population | Q28278062 | ||
| The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 | ||
| Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
| Diurnal variation of aldosterone and plasma renin activity: timing relation to melatonin and cortisol and consistency after prolonged bed rest | Q34281740 | ||
| Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure | Q35820248 | ||
| A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro | Q37365783 | ||
| Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Aten | Q43928917 | ||
| Functional polymorphisms in the mineralocorticoid receptor and amirolide-sensitive sodium channel genes in a patient with sporadic pseudohypoaldosteronism | Q44250092 | ||
| Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines | Q44283416 | ||
| Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study | Q44485270 | ||
| How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? | Q45017405 | ||
| Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives | Q45251130 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| P304 | page(s) | 1-9 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure | |
| P478 | volume | 30 |
| Q37821172 | Aldosterone antagonists in heart failure |
| Q34923747 | Association of aldosterone synthase polymorphism (CYP11B2 -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure |
| Q90327973 | Effect of Genetic and Nongenetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure |
| Q34751971 | Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial |
| Q38040730 | Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure |
| Q34241836 | PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. |
| Q38998634 | Pharmacogenomics of heart failure: a systematic review |
| Q64959338 | Role of Renin-Angiotensin-Aldosterone System Activation in Promoting Cardiovascular Fibrosis and Stiffness. |
| Q39042819 | Role of mineralocorticoid receptor activation in cardiac diastolic dysfunction |
| Q37902667 | What is the risk of hyperkalaemia in heart failure? |
Search more.